Showing results (221-230 of 392) with videos related to
Sort By:
Pageof 40
International Journal of Cancer|September 19, 2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinibChristine Wolf, Angela Garding, Katharina Filarsky, et al.The Journal of Pathology|March 4, 2025
The significance of PAX5 in Merkel cell carcinomaEmil Chteinberg, Julia Kolarova, Julia Vogt, et al.Blood|April 19, 2011
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jan Dürig, et al.Leukemia & Lymphoma|January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trialClemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.Journal of Cancer Research and Clinical Oncology|January 17, 2025
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case reportCarolin Seeling, Sonja Dahlum, Ralf Marienfeld, et al.British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.Leukemia & Lymphoma|April 26, 2013
Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemiaG Doreen te Raa, Jitka Malcikova, Sarka Pospisilova, et al.Leukemia|February 2, 2021
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4<sup>+</sup> T cells in chronic lymphocytic leukemiaPhilipp M Roessner, Laura Llaó Cid, Ekaterina Lupar, et al.Pageof 40